MedTrace Logo

The Effects of Hydromorphone on Responses to Verbal Tasks

NCT02205983 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-10-09

Study results available
· View outcomes & findings →

Summary

In this study, the investigators will examine the effects of hydromorphone, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opioids and opiates in mediating social behavior in humans and other animals, and particularly, in social distress. The investigators have recently shown that buprenorphine, a partial mu-opioid agonist, reduces cortisol responses to stress. Here, the investigators propose to further explore the role of the opioid system in mediating stress responses in humans through the use of hydromorphone, a full mu opioid agonist, in addition to acetaminophen. The investigators hypothesize that like acetaminophen, hydromorphone will reduce both physiological and subjective measures of stress.

Conditions

  • Healthy

Interventions

DRUG

2 mg hydromorphone

We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.

DRUG

1000 mg Acetaminophen

We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.

DRUG

4 mg hydromorphone

We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.

DRUG

dextrose

We are administering dextrose to healthy volunteers for our placebo group.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Harriet de Wit, PhD · University of Chicago

  • Jerome Jaffe, MD · University of Maryland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-07-31
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02205983 on ClinicalTrials.gov